Abstract
Genomic instability is a hallmark of human cancer, and results in widespread somatic copy number alterations. We used a genome-scale shRNA viability screen in human cancer cell lines to systematically identify genes that are essential in the context of particular copy-number alterations (copy-number associated gene dependencies). The most enriched class of copy-number associated gene dependencies was CYCLOPS (Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS) genes, and spliceosome components were the most prevalent. One of these, the pre-mRNA splicing factor SF3B1, is also frequently mutated in cancer. We validated SF3B1 as a CYCLOPS gene and found that human cancer cells harboring partial SF3B1 copy-loss lack a reservoir of SF3b complex that protects cells with normal SF3B1 copy number from cell death upon partial SF3B1 suppression. These data provide a catalog of copy-number associated gene dependencies and identify partial copy-loss of wild-type SF3B1 as a novel, non-driver cancer gene dependency.
Highlights
Despite recent advances in cancer therapeutics, there remains a dearth of effective treatments
We find that wild-type SF3B1 is a non-driver CYCLOPS gene dependency and describe the mechanism behind this dependency
A single gene dependency profile correlated with copy-number profiles of multiple genes from a single genomic region
Summary
Despite recent advances in cancer therapeutics, there remains a dearth of effective treatments. Expanding the number of candidate therapeutic targets in cancer is crucial. Cancer Biology Human Biology and Medicine genes’, which undergo positive selection due to their effects on oncogenes or tumor suppressor genes, represent cancer vulnerabilities that are broadly considered as potential therapeutic targets (Cheung et al, 2011; Eifert and Powers, 2012; Wang et al, 2015). Alterations of nondriver genes, which do not contribute to oncogenesis but are observed, represent an emerging class of candidate therapeutic target that have yet to be fully explored
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have